Login
Super Investors Logos Global Management LP
LG

Logos Global Management LP

Quarterly 13F snapshot: US-listed longs only, no performance figures — 13F data cannot support them.

Portfolio value
$1.86B
Positions
72
Quarter ended
September 30, 2026
Filed
November 16, 2026

Reported portfolio value by quarter (28 quarters reported)

$2.32B $263M
Q4 19 Q2 21 Q4 22 Q2 24 Q4 25 Q3 26

$406M in Q4 2019 → $1.86B now. Hover for any quarter.

Holdings

As reported for the quarter ended September 30, 2026. Activity is the change in share count since the prior quarter's filing.

Holding % of portfolio Activity Shares Value
PP Praxis Precision Medicines I 6.7% Added 63% 425,000 $124M
Revolution Medicines Inc 6.6% Trimmed 14% 600,000 $123M
Ideaya Biosciences Inc 5.9% Trimmed 5.0% 2,850,000 $109M
Erasca Inc 4.7% Trimmed 51% 5,900,000 $86.5M
AS Abivax Sa 4.6% Trimmed 15% 870,000 $86.1M
Cg Oncology Inc 3.7% Trimmed 2.5% 975,000 $69.1M
Disc Medicine Inc 3.6% Added 16% 1,015,000 $66.4M
Biontech Se 3.4% Trimmed 36% 650,000 $63.9M
Tango Therapeutics Inc 2.9% Trimmed 25% 2,150,000 $53.6M
Madrigal Pharmaceuticals Inc 2.7% New 100,000 $50.4M
Enliven Therapeutics Inc 2.7% Added 132% 1,080,000 $49.5M
Dyne Therapeutics Inc 2.6% Added 18% 3,000,000 $48.3M
Ocular Therapeutix Inc 2.5% Added 13% 6,000,000 $46M
Dianthus Therapeutics Inc 2.4% Trimmed 38% 500,000 $44M
Arrivent Biopharma Inc 2.2% Added 35% 1,350,000 $40.9M
Cogent Biosciences Inc 2.2% Added 39% 1,250,000 $40M
Erasca Inc Call 2.0% New 2,500,000 $36.7M
Neurocrine Biosciences Inc 1.9% New 250,000 $35.5M
Belite Bio Inc 1.8% Trimmed 20% 200,000 $34M
Axsome Therapeutics Inc. 1.7% New 175,000 $32.3M
Structure Therapeutics Inc 1.7% Added 100% 1,000,000 $31.3M
Olema Pharmaceuticals Inc 1.5% Unchanged 3,208,875 $27.7M
AL Achieve Life Science Inc 1.4% Trimmed 41% 3,200,000 $25.9M
Maze Therapeutics Inc 1.4% Trimmed 52% 935,000 $25.4M
PM Parabilis Medicines Inc 1.3% Added 43% 750,000 $24.2M
A Apnimed Inc 1.3% New 1,100,000 $24.1M
Yarrow Bioscience Inc 1.2% New 1,026,258 $23.1M
Avalo Therapeutics Inc Call 1.2% New 1,500,000 $23M
Trevi Therapeutics Inc 1.1% Trimmed 23% 1,445,000 $20.7M
Veradermics Inc 1.1% Trimmed 5.6% 170,000 $20.6M
Replimune Group Inc Call 1.1% New 1,500,000 $19.9M
VT Vera Therapeutics Inc 1.0% Trimmed 73% 600,000 $19.4M
Design Therapeutics Inc Call 1.0% New 1,500,000 $18.9M
Sarepta Therapeutics Inc Call 1.0% New 1,000,000 $18.2M
Sarepta Therapeutics Inc 1.0% New 1,000,000 $18.2M
Moonlake Immunotherapeutics 0.9% Trimmed 44% 1,500,000 $17.6M
Summit Therapeutics Inc Call 0.9% New 1,000,000 $16.9M
IH Immunocore Hldgs PLC 0.8% Trimmed 17% 500,000 $15.1M
Biohaven Ltd 0.8% New 1,100,000 $14.7M
Crispr Therapeutics Ag 0.7% Trimmed 17% 250,000 $13.8M
Biohaven Ltd Call 0.7% New 1,000,000 $13.4M
Definium Therapeutics Inc 0.7% Added 338% 350,000 $13.3M
Arcus Biosciences Inc Call 0.7% New 500,000 $12.9M
Entera Bio Ltd 0.7% New 4,411,764 $12.8M
Design Therapeutics Inc 0.7% Trimmed 67% 1,000,000 $12.6M
Compass Pathways PLC Call 0.7% New 1,000,000 $12.4M
Crescent Biopharma Inc. 0.7% Trimmed 55% 850,000 $12.4M
ET Electra Therapeutics Inc 0.6% New 1,000,000 $11.3M
Minerva Neurosciences Inc 0.6% Unchanged 3,288,777 $11M
Lb Pharmaceuticals Inc 0.5% Trimmed 57% 250,000 $9.6M
AL Achieve Life Science Inc Call 0.4% New 1,000,000 $8.09M
Alumis Inc Call 0.4% New 1,000,000 $7.39M
IS Inventiva Sa Call 0.4% New 2,000,000 $7.38M
Eyepoint Inc Call 0.4% New 2,000,000 $6.54M
Viking Therapeutics Inc 0.4% New 200,000 $6.52M
Editas Medicine Inc 0.3% Unchanged 2,222,000 $5.71M
TP Tonix Pharmaceuticals Hldg C 0.3% New 550,000 $5.36M
Opus Genetics Inc 0.3% New 1,000,000 $4.84M
V Vogenx Inc 0.3% New 205,000 $4.67M
Immunovant Inc 0.2% Trimmed 87% 85,000 $2.87M

Showing top 60 of 72 positions.

Timeline of changes

What changed each quarter, from the filings' own share counts. Largest moves first; most recent 8 quarters.

Q3 2026

quarter ended September 30, 2026 · filed November 16, 2026

Company Action Shares changed Value of change % of portfolio
Erasca Inc Trimmed −6,250,000 −$91.6M 4.7%
CT Celldex Therapeutics Inc New Exited −2,100,000 −$78.1M —
VT Vera Therapeutics Inc Trimmed −1,600,000 −$51.7M 1.0%
Madrigal Pharmaceuticals Inc New +100,000 +$50.4M 2.7%
PP Praxis Precision Medicines I Added +165,000 +$48.1M 6.7%
Erasca Inc New +2,500,000 +$36.7M 2.0%
Biontech Se Trimmed −365,000 −$35.9M 3.4%
Neurocrine Biosciences Inc New +250,000 +$35.5M 1.9%
Axsome Therapeutics Inc. New +175,000 +$32.3M 1.7%
Compass Pathways PLC Exited −2,250,000 −$31.8M —

Showing the 10 largest of 88 changes.

Q2 2026

quarter ended June 30, 2026 · filed August 14, 2026

Company Action Shares changed Value of change % of portfolio
Revolution Medicines Inc Trimmed −1,300,000 −$243M 5.6%
Biontech Se New +1,015,000 +$94.4M 4.1%
VT Vera Therapeutics Inc New +2,200,000 +$94.4M 4.1%
Centessa Pharmaceuticals PLC Exited −2,125,000 −$84.4M —
Terns Pharmaceuticals Inc Exited −1,500,000 −$79.1M —
CT Celldex Therapeutics Inc New Added +1,650,000 +$61.4M 3.4%
Cytokinetics Inc Exited −875,000 −$57.7M —
UT United Therapeutics Corp Del Exited −80,000 −$47.4M —
AS Abivax Sa Added +349,000 +$46.5M 5.9%
Madrigal Pharmaceuticals Inc Exited −85,000 −$44.5M —

Showing the 10 largest of 85 changes.

Q1 2026

quarter ended March 31, 2026 · filed May 15, 2026

Company Action Shares changed Value of change % of portfolio
Revolution Medicines Inc Exited −1,000,000 −$79.7M —
Centessa Pharmaceuticals PLC Added +1,925,000 +$76.5M 4.2%
Cidara Therapeutics Inc Exited −310,000 −$68.5M —
UT United Therapeutics Corp Del New +80,000 +$47.4M 2.4%
Madrigal Pharmaceuticals Inc New +85,000 +$44.5M 2.2%
Terns Pharmaceuticals Inc Added +750,000 +$39.5M 3.9%
Cytokinetics Inc Added +575,000 +$37.9M 2.9%
Avidity Biosciences Inc Exited −500,000 −$36.1M —
Jazz Pharmaceuticals PLC Exited −200,000 −$34M —
AS Abivax Sa Added +275,000 +$30.6M 3.8%

Showing the 10 largest of 77 changes.

Q4 2025

quarter ended December 31, 2025 · filed February 17, 2026

Company Action Shares changed Value of change % of portfolio
PP Praxis Precision Medicines I Added +250,000 +$73.7M 6.7%
Akero Therapeutics Inc Exited −1,200,000 −$57M —
Arvinas Inc Exited −5,575,000 −$47.5M —
Terns Pharmaceuticals Inc New +750,000 +$30.3M 1.8%
Ideaya Biosciences Inc Added +875,000 +$30.2M 6.5%
Tango Therapeutics Inc Added +3,250,000 +$28.8M 2.2%
Immunovant Inc Added +1,100,000 +$28M 2.1%
Arcus Biosciences Inc New +1,050,000 +$25M 1.5%
Moonlake Immunotherapeutics New +1,750,000 +$23.1M 1.4%
Acadia Pharmaceuticals Inc New +850,000 +$22.7M 1.4%

Showing the 10 largest of 73 changes.

Q3 2025

quarter ended September 30, 2025 · filed November 14, 2025

Company Action Shares changed Value of change % of portfolio
SS SPDR Series Trust Exited −1,000,000 −$82.9M —
Revolution Medicines Inc New +1,000,000 +$46.7M 4.2%
AS Abivax Sa New +415,000 +$35.2M 3.2%
Jazz Pharmaceuticals PLC Trimmed −250,000 −$33M 2.4%
Ideaya Biosciences Inc Trimmed −1,095,000 −$29.8M 5.5%
Verastem Inc Added +3,050,000 +$26.9M 3.2%
TP Teva Pharmaceutical Inds Ltd Exited −1,500,000 −$25.1M —
UT United Therapeutics Corp Del Exited −85,000 −$24.4M —
Vaxcyte Inc New +625,000 +$22.5M 2.0%
Protagonist Therapeutics Inc New +300,000 +$19.9M 1.8%

Showing the 10 largest of 66 changes.

Q2 2025

quarter ended June 30, 2025 · filed August 14, 2025

Company Action Shares changed Value of change % of portfolio
SS SPDR Series Trust New +1,000,000 +$82.9M 9.2%
Jazz Pharmaceuticals PLC New +450,000 +$47.8M 5.3%
Nuvalent Inc Exited −500,000 −$35.5M —
TP Teva Pharmaceutical Inds Ltd Exited −1,700,000 −$26.1M —
TP Teva Pharmaceutical Inds Ltd New +1,500,000 +$25.1M 2.8%
Biogen Inc New +200,000 +$25.1M 2.8%
UT United Therapeutics Corp Del New +85,000 +$24.4M 2.7%
Arvinas Inc New +3,300,000 +$24.3M 2.7%
Xenon Pharmaceuticals Inc Exited −650,000 −$21.8M —
Neurocrine Biosciences Inc New +150,000 +$18.9M 2.1%

Showing the 10 largest of 59 changes.

Q1 2025

quarter ended March 31, 2025 · filed May 15, 2025

Company Action Shares changed Value of change % of portfolio
Cytokinetics Inc Exited −900,000 −$42.3M —
VT Vera Therapeutics Inc Exited −875,000 −$37M —
Nuvalent Inc New +500,000 +$35.5M 6.3%
Merus N V Exited −750,000 −$31.5M —
Insmed Inc Exited −450,000 −$31.1M —
Neurocrine Biosciences Inc Exited −200,000 −$27.3M —
TP Teva Pharmaceutical Inds Ltd New +1,700,000 +$26.1M 4.6%
Vaxcyte Inc Exited −300,000 −$24.6M —
Xenon Pharmaceuticals Inc New +650,000 +$21.8M 3.9%
Jazz Pharmaceuticals PLC Exited −175,000 −$21.6M —

Showing the 10 largest of 46 changes.

Q4 2024

quarter ended December 31, 2024 · filed February 14, 2025

Company Action Shares changed Value of change % of portfolio
Disc Medicine Inc Trimmed −735,000 −$46.6M 1.5%
Biontech Se New +300,000 +$34.2M 4.0%
Insmed Inc New +450,000 +$31.1M 3.6%
CT Celldex Therapeutics Inc New Exited −900,000 −$30.6M —
Ionis Pharmaceuticals Inc Exited −750,000 −$30M —
Apellis Pharmaceuticals Inc Exited −1,000,000 −$28.8M —
Neurocrine Biosciences Inc New +200,000 +$27.3M 3.2%
Cytokinetics Inc Added +500,000 +$23.5M 5.0%
Ideaya Biosciences Inc Added +900,000 +$23.1M 9.0%
Galapagos Nv Exited −800,000 −$23M —

Showing the 10 largest of 62 changes.

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support